NCT03852901View on ClinicalTrials.gov

Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 28, 2019

Primary Completion Date

November 12, 2020

Study Completion Date

December 13, 2021

Conditions
EmpaglifozinPhysiological Effects of DrugsHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors
Interventions
DRUG

empagliflozin (Jardiance) 25 mg

Oral empagliflozin 25 mg/day x 14 days

Trial Locations (1)

21224

National Institute on Aging, Clinical Research Unit, Baltimore

All Listed Sponsors
lead

National Institute on Aging (NIA)

NIH

NCT03852901 - Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production | Biotech Hunter | Biotech Hunter